New narcolepsy drug TAK-861 put to the test in withdrawal trial
NCT ID NCT07363720
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether TAK-861 can control symptoms of narcolepsy type 1, a condition causing sudden sleep attacks and muscle weakness. About 88 adults will take TAK-861 for several months, then some will switch to a placebo to see if symptoms return. The goal is to see if the drug's effect lasts and is better than no treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-861
What this could lead to
If it works, this could provide a new treatment option to control excessive daytime sleepiness and sudden muscle weakness in people with narcolepsy type 1.
What could go wrong
This is a small Phase 3 trial with only 88 participants, and the main test is a short 4-week withdrawal period. The drug may not prove better than placebo, and long-term safety is not yet established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NARCOLEPSY TYPE 1 (NT1) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda Site 1
RECRUITINGRedwood City, California, 94063, United States
-
Takeda Site 10
RECRUITINGToulouse, 31059, France
-
Takeda Site 11
RECRUITINGSchwerin, Mecklenburg-Vorpommern, 19053, Germany
-
Takeda Site 12
RECRUITINGHeemstede, 2103 SW, Netherlands
-
Takeda Site 13
RECRUITINGBarmelweid, Canton of Aargau, 5017, Switzerland
-
Takeda Site 14
RECRUITINGBern, 3010, Switzerland
-
Takeda Site 15
RECRUITINGCleveland, Ohio, 44195, United States
-
Takeda Site 16
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Takeda Site 17
RECRUITINGDurham, North Carolina, 27710-4000, United States
-
Takeda Site 18
RECRUITINGWinston-Salem, North Carolina, 27103, United States
-
Takeda Site 2
RECRUITINGCincinnati, Ohio, 45245, United States
-
Takeda Site 3
RECRUITINGColumbia, South Carolina, 29201, United States
-
Takeda Site 4
RECRUITINGBrandon, Florida, 33511, United States
-
Takeda Site 5
RECRUITINGAustin, Texas, 78731, United States
-
Takeda Site 6
RECRUITINGMiami, Florida, 33155, United States
-
Takeda Site 7
RECRUITINGSouthfield, Michigan, 48075, United States
-
Takeda Site 8
RECRUITINGMontpellier, 34295, France
-
Takeda Site 9
RECRUITINGParis, 75013, France